Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 7:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 891 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypertension Treatment Clear all
Terminated Phase 3 Interventional Results available

Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

NCT01176565
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Intravenous nicardipine hydrochloride
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
116
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 10, 2026, 7:16 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension

NCT00446511
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan, Enalapril, placebo matched to enalapril, placebo matched to valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 10, 2026, 7:16 AM EDT
Completed Phase 2 Interventional Results available

Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension

NCT00705133
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Interventions
Treprostinil
Drug
Lead sponsor
Rajan Saggar
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 10, 2026, 7:16 AM EDT
Terminated Not applicable Interventional Results available

ActiV.A.C.+ Compression Therapy Versus Compression Therapy Alone for the Treatment of Chronic Venous Ulcerations

NCT01528293
View directory record Official record
Conditions
Chronic Venous Hypertension With Ulcer
Interventions
ActiVAC System, Compression therapy
Device · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 10, 2026, 7:16 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans

NCT02386293
View directory record Official record
Conditions
Hypertension, Obesity, Stress, Psychological, Blood Pressure
Interventions
Irbesartan, Placebo
Drug · Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Sep 10, 2026, 7:16 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension

NCT05314439
View directory record Official record
Conditions
Hypertension
Interventions
ION904, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Cypress, California • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 10, 2026, 7:16 AM EDT
Terminated Phase 3 Interventional Results available

Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

NCT01392495
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Sep 10, 2026, 7:16 AM EDT
Completed Phase 2 Interventional

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

NCT00069719
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Glaucoma therapy
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Multiple Locations Throughout the US Sponsored by Alcon of, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Sep 10, 2026, 7:16 AM EDT
Terminated Phase 2 Interventional Results available

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

NCT02261883
View directory record Official record
Conditions
Persistent Pulmonary Hypertension of the Newborn
Interventions
IV Remodulin, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
1 Hour to 14 Days
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
14
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 10, 2026, 7:16 AM EDT
Completed Phase 2 Interventional

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT00326092
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide/Timolol
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 10, 2026, 7:16 AM EDT
Completed Phase 2 Interventional

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

NCT03727451
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
Interventions
iNO
Combination Product
Lead sponsor
Bellerophon
Industry
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 10, 2026, 7:16 AM EDT
Completed No phase listed Observational

Steroid Eyedrop Adherence After Trabeculectomy

NCT03402802
View directory record Official record
Conditions
Glaucoma, Adherence, Patient
Interventions
monitoring of adherence with medication
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 100 Years
Enrollment
92 participants
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Sep 10, 2026, 7:16 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

NCT00654875
View directory record Official record
Conditions
Essential Hypertension
Interventions
Aliskiren, Placebo to Aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Zanesville, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Sep 10, 2026, 7:16 AM EDT
Not listed Phase 4 Interventional

IV Double and Triple Concentrated Nicardipine for Stroke and ICH

NCT00325793
View directory record Official record
Conditions
Hypertension
Interventions
Nicardipine
Drug
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2006 · Synced Sep 10, 2026, 7:16 AM EDT
Withdrawn Phase 3 Interventional

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00760916
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Sep 10, 2026, 7:16 AM EDT
Recruiting No phase listed Observational

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

NCT06151730
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 10, 2026, 7:16 AM EDT
Completed Not applicable Interventional Results available

Uncontrolled Hypertension Among the Homeless

NCT05187013
View directory record Official record
Conditions
Hypertension
Interventions
mHealth for Hypertension in Homeless Persons
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
21 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 10, 2026, 7:16 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension

NCT00649389
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
228
States / cities
Birmingham, Alabama • Columbiana, Alabama • Gulf Shores, Alabama + 225 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 10, 2026, 7:16 AM EDT
Completed Phase 1 Interventional

The Effect of the Patient Activation Measure on Chronic Care

NCT00299468
View directory record Official record
Conditions
Hypertension
Interventions
Patient Activation Measure Intervention Package
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2008 · Synced Sep 10, 2026, 7:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications

NCT03506568
View directory record Official record
Conditions
Medication Adherence, Glaucoma
Interventions
Devers Drop Device (D3) app
Device
Lead sponsor
Universal Adherence LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 10, 2026, 7:16 AM EDT
Recruiting Not applicable Interventional

Intensive Patient Referral and Education Program Prior to Renal Replacement Therapy

NCT06397456
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
In-Person Patient Education, Commitment to Change, Blood pressure monitoring, Written Patient Education, Text-based reinforcement for CKD self-management, Community-based education session, reinforcement for self-management, Text-based reinforcement for general health self-management
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 10, 2026, 7:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study

NCT00425945
View directory record Official record
Conditions
Hypertension
Interventions
Pine Bark Extract (Flavangenol®)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Sep 10, 2026, 7:16 AM EDT
Terminated No phase listed Observational

Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

NCT01494896
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Jacksonville, Florida • Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 10, 2026, 7:16 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Functional and Structural Imaging for Glaucoma

NCT01957267
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 85 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2031
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 10, 2026, 7:16 AM EDT